ADVERTISEMENT

marginal zone lymphoma

Research in Review

Novel Prognostic Index Designed for Patients With MZL

07/19/2017

JCP Editors

A new prognostic tool improves personalized treatment for patients with marginal zone lymphoma (MZL), according to recent research published in Blood (online July 2017;...

A new prognostic tool improves personalized treatment for patients with marginal zone lymphoma (MZL), according to recent research published in Blood (online July 2017;...

A new...

07/19/2017

Journal of Clinical Pathways

Research in Review

New Biomarker for Relapsed or Refractory MZL Identified

02/27/2017

JCP Editors

Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...

Patients with marginal zone lymphoma (MZL) who underwent prior therapy with an anti-CD20 antibody regimen may be treatable with a tyrosine kinase inhibitor approved for other blood cancers, according to research...

...

02/27/2017

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

October 5 ⁠–⁠ October 6

October 14 ⁠–⁠ October 16

October 16 ⁠–⁠ October 19

October 19 ⁠–⁠ October 20

October 26 ⁠–⁠ October 27

October 29 ⁠–⁠ November 2

November 1 ⁠–⁠ November 2

November 6 ⁠–⁠ November 8

NEI Congress

November 7 ⁠–⁠ November 10

November 8 ⁠–⁠ November 10

See Full Calendar

Advertisement

Advertisement